Benuvia Operations Partners with Leading Pharma for Dronabinol
Benuvia Operations Forms Strategic Supply Agreement
Benuvia Operations, LLC has solidified a critical partnership by signing a multi-year supply agreement with a major U.S. pharmaceutical company for its Dronabinol API. This substantial collaboration is set to enhance the development of cannabinoid-based medications, aligning with the ongoing trend towards improving patient access to quality treatments.
Significance of the Agreement
This partnership allows the pharmaceutical company to utilize Benuvia's U.S. Drug Master File (DMF) for Dronabinol when filing with the U.S. Food and Drug Administration (FDA). This feature not only streamlines the regulatory process but also signifies a mutual commitment to quality and compliance in the evolving pharmaceutical landscape.
Quality and Reliability in Production
Benuvia's reputation as a reliable supplier stems from its commitment to manufacturing high-quality API products, including Dronabinol. Their facility adheres to stringent regulatory standards and demonstrates excellence in operational reliability and scientific proficiency. This ensures that clients receive consistent, compliant products throughout all stages of drug development, from initial research through to commercial production.
CEO Insights on the Industry
According to Terry Novak, CEO of Benuvia, "This partnership reinforces our role as a trusted supplier of pharmaceutical-grade cannabinoid APIs. As the demand for high-quality, U.S.-manufactured pharmaceutical ingredients continues to rise, we are dedicated to supporting our partners' development initiatives with unparalleled scientific and operational excellence."
Impactful Manufacturing Capabilities
Benuvia operates a state-of-the-art, FDA-audited, and DEA-registered manufacturing facility. This cutting-edge setting is equipped to handle the complexities involved in producing drug substances and finished dosage forms, particularly for Schedule I-V controlled substances. The company provides a variety of services, including analytical development and regulatory support, establishing itself as a leading entity in the pharmaceutical manufacturing arena.
About Benuvia Operations
Benuvia Operations, LLC is a globally recognized Contract Development and Manufacturing Organization (CDMO) and Active Pharmaceutical Ingredient (API) supplier. The company specializes in delivering comprehensive development and manufacturing services targeted at pharmaceutical and biotech entities, particularly for small-molecule APIs, with extensive knowledge of cannabinoids and other controlled substances.
Benuvia's Commitment to Excellence
With its 83,000 square foot manufacturing facility, Benuvia is well-prepared to safely manage the complexities that come with Schedule I-V controlled substances, offering a full range of solutions spanning the drug development lifecycle. By fostering strong partnerships and prioritizing quality, Benuvia ensures that it meets the rigorous demands of the pharmaceutical sector.
Frequently Asked Questions
What is the nature of Benuvia's supply agreement?
Benuvia has signed a multi-year supply agreement with a prominent U.S. pharmaceutical company to provide Dronabinol API, facilitating product development efforts.
How will this agreement benefit the pharmaceutical company?
The agreement allows the pharmaceutical company to reference Benuvia's U.S. Drug Master File (DMF) when filing with the FDA, which aids regulatory compliance and expedites the product development process.
What services does Benuvia offer?
Benuvia provides a wide range of services, including drug substance and product manufacturing, analytical development, and regulatory support for controlled substances.
Where is Benuvia's manufacturing facility located?
Benuvia operates a fully integrated, FDA-audited, and DEA-registered manufacturing facility located in Texas.
What is Benuvia's focus regarding controlled substances?
Benuvia specializes in small-molecule APIs and finished dosage products, particularly with experience in cannabinoids and other controlled substances, ensuring high-quality production standards.
About The Author
Contact Kelly Martin privately here. Or send an email with ATTN: Kelly Martin as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.